Halberd Corporation Announces Breakthrough in Candida auris Treatment
Halberd Corporation announced a breakthrough in treating Candida auris, a multidrug-resistant fungal pathogen, using a novel extracorporeal method that combines lasers and metallic nanoparticles. This method has shown success in eradicating the fungus in as little as 5 minutes. Dr. Cooper from Youngstown State University emphasized the treatment's potential to mitigate the public health threat posed by such infections. Halberd has also previously demonstrated similar effectiveness against Escherichia coli and antibiotic-resistant bacteria, reinforcing its technology's versatility and potential impact on healthcare costs and patient outcomes.
- Achieved eradication of Candida auris in just 5 minutes.
- Novel treatment method shows promise against multidrug-resistant pathogens.
- Past successes in eliminating other resistant pathogens like E. coli enhance credibility.
- None.
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report: https://www.youtube.com/watch?v=WffAP1fJhy0
"Halberd's innovative approach offers a highly effective solution for treating Candida auris infections and could help to reduce the spread of this pathogen in healthcare settings," stated Dr. Cooper, Professor, Department of Chemical and Biological Sciences at Youngstown State University. "This approach potentially offers a highly effective solution for treating this serious health concern, and we are committed to bring this treatment to patients in need."
William A. Hartman, Halberd's Chairman, President & CEO commented, "An effective treatment of Candida auris would help to address the growing public health threat posed by multidrug-resistant pathogens and the increasing frequency of fungal infections. Halberd's patented breakthrough technology has shown potentially universal capacity to eradicate pathogens. In particular, our patent protected methodologies successfully eradicated in vitro viruses (SARS-CoV-2), inflammatory cytokines, excitatory neurotransmitters (glutamate), antibiotic-resistant bacteria, and now deadly Candida auris fungus. Halberd's patent protected technologies are designed to have a major impact on medical treatments worldwide and lead to improved patient outcomes, fewer deaths, greater longevity and reduced healthcare costs. Halberd's process is effective in minutes, NOT lengthy treatment protocols with potentially harmful and too often ineffectual antibiotics."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Youngstown State University
Youngstown State University is a public university in Youngstown, Ohio, and is composed of 5 undergraduate colleges. The University has over 150 undergraduate degree programs and 50 graduate degree programs serving over 12,000 students in studies up to the doctoral level. Beyond its current student body, the university has more than 125,000 alumni across the country and around the world.
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to four issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/739051/Halberd-Corporation-Announces-Breakthrough-in-Candida-auris-Treatment
FAQ
What breakthrough did Halberd Corporation achieve on February 13, 2023?
How long does Halberd's treatment take to eradicate Candida auris?
What is the significance of Candida auris according to Halberd's press release?
What are the implications of Halberd's new treatment for healthcare?
What other pathogens has Halberd successfully targeted with its technology?
